# Amlodipine Diabetic Hypertension Efficacy Response Trial

> **NCT00159692** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 739 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Amlodipine

## Key facts

- **NCT ID:** NCT00159692
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 739 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00159692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00159692, "Amlodipine Diabetic Hypertension Efficacy Response Trial". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00159692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*